BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.30, which may not compare to the analyst estimate of $0.06. Revenue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE